Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
  • A61K31/07—Retinol compounds, e.g. vitamin A
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/67—Vitamins
  • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
  • A61K31/716—Glucans
  • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
  • A61K8/73—Polysaccharides
  • A61K8/732—Starch; Amylose; Amylopectin; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
  • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
  • A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
  • A61K8/8152—Homopolymers or copolymers of esters, e.g. (meth)acrylic acid esters; Compositions of derivatives of such polymers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/10—Anti-acne agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/08—Anti-ageing preparations
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/10—Washing or bathing preparations
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
  • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
  • A61K2800/88—Two- or multipart kits

Definitions

• the present invention relates to methods of treating skin in need of treatment with retinoids, which comprise cleansing the skin with a cleansing composition comprising a low irritation polymeric cleansing agent prior to treating with the retinoids. These methods improve the activity of the retinoids and can enable superior outcomes.
• Retinoids have been used in a variety of prescription and cosmetic topical compositions for treating skin conditions such as signs of skin aging, acne, and rosacea.
• tretinoin is used in prescription acne products as well as prescription anti-wrinkle products such as RENOVA® commercially available from Obagi Medical Products, Inc.
• Retinol is used in cosmetics for example NEUTROGENA® Rapid Wrinkle Repair® commercially available from Johnson & Johnson Consumer Inc.
• NEUTROGENA® Rapid Wrinkle Repair® is used to fade the look of wrinkles in skin, smooth fine lines, improve skin texture, and brighten skin tone.
• Retinol in particular has proven to be a highly efficacious and cost effective cosmetic ingredient, and improvements in its activity and delivery into the skin are always desirable.
• Applicants have now discovered that pretreatment of skin by cleansing with a cleansing composition comprising particular low irritation polymeric cleansing agents (LIPCAs) before topical application of a retinoid surprisingly increases the activity of the retinoid.
• LIPCAs low irritation polymeric cleansing agents
• Multi-step skin care regimens are known.
• WO 2010/085753 discloses a treatment regimen including cleansing at least a portion of an area of skin afflicted with rosacea with a cleanser; applying a composition comprising metronidazole to at least a portion of the afflicted area, and applying an anti-redness composition to at least a portion of the cleansed and metronidazole-treated area.
• Use of “gentle” skin cleansers CETAPHIL® (Galderma Laboratories) and NU-DERM® (Obagi Medical Products, Inc.) are disclosed.
• optional application of compositions comprising retinoids and other ingredients are disclosed.
• a cleansing composition comprising a LIPCA, potassium acrylates copolymer, is commercially available from Johnson & Johnson Consumer Inc. as NEUTROGENA® Ultra Gentle Daily Cleanser.
• the invention provides a method for treating skin, comprising in sequence: (a) cleansing skin in need of treatment for signs of skin aging, acne, or rosacea with a cleansing composition comprising a superhydrophilic amphiphilic copolymer (SAC); and (b) topically applying to the skin a leave-on composition comprising a retinoid.
• a cleansing composition comprising a superhydrophilic amphiphilic copolymer (SAC)
• SAC superhydrophilic amphiphilic copolymer
• the invention also provides a kit comprising: (a) a cleansing composition comprising a SAC; and (b) a leave-on composition comprising a retinoid.
• the invention further provides a method of increasing the activity of a retinoid, comprising cleansing skin in need of treatment with retinoids with a cleansing composition comprising a SAC prior to contacting the skin with the retinoid.
• the invention also provides a method for treating skin, comprising in sequence: (a) cleansing skin in need of treatment for signs of skin aging, acne, or rosacea with a cleansing composition comprising a low molecular weight hydrophobically modified polymer (HMP); and (b) topically applying to the skin a leave-on composition comprising a retinoid.
• a cleansing composition comprising a low molecular weight hydrophobically modified polymer (HMP)
• HMP hydrophobically modified polymer
• the invention also provides a kit comprising: (a) a cleansing composition comprising a low molecular weight HMP; and (b) a leave-on composition comprising a retinoid.
• the invention further provides a method of increasing the activity of a retinoid, comprising cleansing skin in need of treatment with retinoids with a cleansing composition comprising a low molecular weight HMP prior to contacting the skin with the retinoid.
• topically applying means directly laying on or spreading on outer skin, the scalp, or hair, e.g., by use of the hands or an applicator such as a wipe, roller, or spray.
• cosmetic refers to a beautifying substance or preparation which preserves, restores, bestows, simulates, or enhances the appearance of bodily beauty or appears to enhance the beauty or youthfulness, specifically as it relates to the appearance of tissue or skin.
• cosmetically effective amount means an amount of a physiologically active compound or composition sufficient for treating one or more signs of skin aging, but low enough to avoid serious side effects.
• the cosmetically effective amount of the compound or composition will vary with the particular condition being treated, the age and physical condition of the end user, the severity of the condition being treated/prevented, the duration of the treatment, the nature of other treatments, the specific compound or product/composition employed, the particular cosmetically-acceptable carrier utilized, and like factors.
• cosmetically acceptable means that the ingredients the term describes are suitable for use in contact with tissues (e.g., the skin or hair) without undue toxicity, incompatibility, instability, irritation, allergic response, or the like.
• a “cosmetically acceptable active agent” is a compound (synthetic or natural) that has a cosmetic or therapeutic effect on the skin or hair.
• treating refers to mitigating, reducing, preventing, improving, or eliminating the presence or signs of a condition or disorder.
• the present invention is suitable for treating signs of skin aging.
• signs of skin aging includes the presence of lines and wrinkles, loss of elasticity, uneven skin, and blotchiness.
• the sign of aging is the presence of lines and wrinkles and/or loss of elasticity.
• wrinkle includes fine lines, fine wrinkles, or coarse wrinkles.
• wrinkles include, but are not limited to, fine lines around the eyes (e.g., “crow's feet”), forehead and cheek wrinkles, frown-lines, and laugh-lines around the mouth.
• loss of elasticity includes loss of elasticity or structural integrity of the skin or tissue, including but not limited to sagging, lax and loose tissue.
• the loss of elasticity or tissue structure integrity may be a result of a number of factors, including but not limited to disease, aging, hormonal changes, mechanical trauma, environmental damage, or the result of an application of products, such as a cosmetics or pharmaceuticals, to the tissue.
• “uneven skin” means a condition of the skin associated with diffuse or mottled pigmentation, which may be classified as hyperpigmentation, such as post-inflammatory hyperpigmentation.
• blotchiness means a condition of the skin associated with redness or erythema.
• the invention is also suitable for treating acne.
• acne refers to disorders resulting from the actions of hormones and other substances on the sebaceous glands and hair follicles, typically leading to clogged pores and the formation of inflammatory or non-inflammatory lesions on the skin. Specifically, it relates to blemishes, lesions, or pimples, pre-emergent pimples, blackheads, and/or whiteheads.
• pre-emergent pimple is an inflamed follicle that are not visually apparent on the surface of the skin with the naked eye (e.g., as a lesion).
• rosacea means skin with persistent erythema with or without papules, pustules, or nodules.
• a percentage or concentration refers to a percentage or concentration by weight (i.e., % (W/W). Unless stated otherwise, all ranges are inclusive of the endpoints, e.g., “from 4 to 9” includes the endpoints 4 and 9.
• the skin prior to treating skin with a retinoid, is cleansed with a cleansing composition comprising a low irritation polymeric cleansing agent (LIPCA).
• LIPCA low irritation polymeric cleansing agent
• the LIPCA comprises at least one superhydrophilic amphiphilic copolymer (SAC).
• SAC superhydrophilic amphiphilic copolymer
• Synthetic routes for achieving the SACs of the present invention include via post-polymerization modification of precursor polymers comprising superhydrophilic repeat units to render some repeat units amphiphilic.
• Nonlimiting examples include the reaction of superhydrophilic polymers comprised of repeat units comprising multiple hydroxyl functionalities, for example, starch, hydroxyethylcellulose, dextran, inulin, pullulan, poly(glyceryl methacrylate), poly[tris(hydroxymethyl)acrylamidomethane)], or poly(sucrose methacrylate), with reagents that will result in amphiphilic repeat units.
• suitable reaction schemes include:
• the SAC for use in the present invention is a polymer having multiple hydroxyl functionalities that is post-polymerization modified to convert some of the repeat units to amphophilic repeat units.
• the polymer e.g., a starch such as a starch dextrin polymer
• the polymer is esterified with an alkenyl succinic anhydride to convert some of the superhydrophilic anhydroglucose units to ARUs.
• the structure of one suitable resulting SAC may be the C-6 sodium dextrin alkenylsuccinate, represented below:
• alkenyl succinate esters of polysaccharides may be synthesized as described, for example, in U.S. Pat. No. 2,661,349 incorporated herein by reference.
• the modification of the sugar repeat units may also occur at the C-2, C-3 or C-4 positions in addition to the C-6 position shown above.
• the SACs derived from the reaction of the starting polysaccharide with the hydrophobic reagent comprise a polysaccharide bound with the hydrophobic reagent.
• the SAC is a starch-based polysaccharide modified with one or more hydrophobic reagents.
• suitable starches include those derived from such plants as corn, wheat, rice, tapioca, potato, sago, and the like. Such starches can be of a native variety or those developed by plant breeding or by gene manipulation. In an embodiment of the invention, the starches include either the waxy versions of such starches (containing less than 5% amylose), high amylose starches (containing more than 40% amylose), those with a modified chain length (such as those disclosed in U.S. Pat. No. 5,954,883, the disclosure of which is incorporated by reference herein), and/or combinations thereof.
• the starting starch is potato starch or tapioca starch. In certain other preferred embodiments, the starting starch is a waxy potato starch or waxy tapioca starch.
• the starch-based polysaccharide is modified by dissolving such low molecular weight starch or “dextrin” in water and reacting such starch with a hydrophobic reagent. The starch is desirably processed to lower its molecular weight by techniques known in the art, e.g., action of acid and heat, enzymatic, or thermal processing.
• the viscosity of the aqueous solution of the polymeric surfactant is desirably low to minimize the detrimental effect of a high solids level of surfactant with pumping or flow of the solution.
• the Brookfield viscosity measured at room temperature (about 23° C.) at 200 rpm using spindle #3 for the polymeric surfactants of this invention may be less than about 1000 cps at 10% aqueous solids based on the total weight of the solution.
• the Brookfield viscosity measured at room temperature (about 23° C.) at 200 rpm using spindle #3 of the 10% aqueous solution may be less than about 25 cps.
• the Brookfield viscosity measured at room temperature (about 23° C.) at 200 rpm using spindle #3 of a 10% aqueous solution will be less than about 10 cps.
• the starch-based polysaccharide is modified with alkenyl succinic anhydride.
• alkenyl succinic anhydride is dodecenylsuccinic anhydride (DDSA).
• DDSA dodecenylsuccinic anhydride
• Exemplary treatment levels of the DDSA, on the dry basis of low molecular weight ranges from about 3 to about 25%. In another embodiment, the treatment level may be from about 5 to about 15% DDSA based on the dry weight of low molecular weight starting starch.
• the SAC is derived from the reaction of the starting polysaccharide and DDSA, and the bound DDSA on the starch-based polysaccharide may be of from about 3 about 15% based on the weight of dry starch. In another embodiment, the bound DDSA will be between 5 and 12% based on the dry weight of starch.
• the hydrophobic reagent is a highly branched version of DDSA containing a 12 carbon side chain made from tetramerization of propene. It has been found that when the tetrapropene is then reacted with maleic anhydride in an ene-type reaction, it forms highly branched tetrapropenyl succinic anhydride (TPSA). Because this material is a slightly viscose oil and has acceptable water solubility (e.g., at about 2-5% in water at 23° C.), this reagent is capable of reacting favorably with the low molecular weight polysaccharide. In an embodiment of this invention, therefore, the hydrophobic reagent used to modify the low molecular weight starch may be TPSA.
• the starch-based polysaccharide is modified with a long chain quaternary compound having at least one chain containing 3 or more carbon atoms.
• the long chain quaternary compound has at least one chain containing 6 or more and more preferably 12 or more carbon atoms, such as 3-chloro-2-hydroxypropyl-dimethyldodecylammonium chloride (sold commercially as QUAB® 342 by QUAB Chemicals) or the epoxide form of such compound, 2,3 epoxypropyldimethyldodecylammonium chloride.
• the SAC is a starch-based polysaccharide derived from potato or tapioca modified with dodecenyl succinic anhydride, wherein the SAC has a mole percent of amphiphilic units that is at least 5 but less than 10% and a weight average molecular weight that is less than about 200,000.
• polysaccharides are suitable for use in the SAC.
• Such polysaccharides may be derived from plant sources and those based on sugar-type repeat units.
• Some non-limiting examples of these polysaccharides are guar, xanthan, pectin, carrageenan, locust bean gum, and cellulose, including physical and chemically modified derivatives of the above.
• physical, chemical and enzymatic degradation of these materials may be necessary to reduce the molecular weight to the desired range to provide the viscosity for the desired application.
• Chemical modification can also be performed to provide additional functional properties (e.g., cationic, anionic or non-ionic) such as treatment with propylene oxide (PO), ethylene oxide (EO), alkyl chlorides (alkylation) and esterification such as 3-chloro-2-hydroxypropyl-trimethylammonium chloride, sodium tripolyphosphate, chloroacetic acid, epichlorohydrin, phosphorous oxychloride and the like.
• additional functional properties e.g., cationic, anionic or non-ionic
• PO propylene oxide
• EO ethylene oxide
• alkyl chlorides alkylation
• esterification such as 3-chloro-2-hydroxypropyl-trimethylammonium chloride, sodium tripolyphosphate, chloroacetic acid, epichlorohydrin, phosphorous oxychloride and the like.
• the LIPCA comprises at least one low molecular weight hydrophobically modified polymer (HMP).
• HMP low molecular weight hydrophobically modified polymer
• Suitable low molecular weight HMPs, and suitable cleansing compositions for use in the invention containing them, are described for example in U.S. Pat. No. 8,025,902, the disclosure of which is incorporated by reference herein.
• low molecular weight HMPs include low-molecular weight acrylic, other ethylenically-unsaturated polymers, polyesters, polycarbonates, polyanhydrides, polyamides, polyurethanes, polyureas, polyimides, polysulfones, polysulfides, combinations of two or more thereof, and the like.
• Suitable low molecular weight acrylic polymers include hydrophobically-modified acrylic, polysaccharide, cellulose, starch polymers, combinations of two or more thereof, and the like.
• Suitable low molecular weight acrylic polymers include hydrophobically-modified acrylic polymers, as well as other acrylic polymers, any of which may be formed via solution, suspension, precipitation, dispersion, emulsion, inverse emulsion, microemulsion, micellar polymerization methods, and combinations of two or more thereof.
• the acrylic polymers for use in the present invention may be derived from any one or more monomers selected from the group consisting of (meth)acrylates, (meth)acrylamides, vinyl ethers, esters, and amides, allyl ethers, esters, amines, and amides, itaconates, crotonates, styrenics, and olefins.
• the acrylic polymers may be comprised of monomers that are nonionic hydrophilic, nonionic hydrophobic, anionic, cationic, zwitterionic, nonassociative macromeric, associative macromeric, or multifunctional/crosslinking in nature.
• low molecular weight polymer refers to a polymer having a number average molecular weight (M n ) of about 100,000 or less as measured by gel permeation chromatography (GPC) calibrated with a poly(methyl methacrylate) (PMMA) standard.
• M n number average molecular weight
• low-molecular weight polymers are those having molecular weight ranges of from about 5,000 to about 80,000 M n , more preferably from about 10,000 to about 50,000 M n , and more preferably between about 15,000 and 40,000 M n .
• the polymeric materials useful in this invention are preferably non-crosslinked, linear acrylic copolymers that are very mild to the skin and mucosa. These non-crosslinked, linear polymers are preferably of low molecular weight having a M n of 100,000 or less.
• the copolymeric compound is polymerized from at least two monomeric components.
• the first monomeric component is selected from one or more ⁇ , ⁇ -ethylenically unsaturated monomers containing at least one carboxylic acid group.
• This acid group can be derived from monoacids or diacids, anhydrides of dicarboxylic acids, monoesters of diacids, and salts thereof.
• the second monomeric component is hydrophobically modified (relative to the first monomeric component) and is selected from one or more ⁇ , ⁇ -ethylenically unsaturated non-acid monomers containing a C 1 to C 9 alkyl group, including linear and branched C 1 to C 9 alkyl esters of (meth)acrylic acid, vinyl esters of linear and branched C 1 to C 10 carboxylic acids, and mixtures thereof.
• the second monomeric component is represented by the formula:
• R is hydrogen or methyl; X is —C(O)OR 1 or —OC(O)R 2 ; R 1 is linear or branched C 1 to C 9 alkyl; and R 2 is hydrogen or linear or branched C 1 to C 9 alkyl.
• R 1 and R 2 is linear or branched C 1 to C 8 alkyl and in a further aspect R 1 and R 2 are linear or branched C 2 to C 5 alkyl.
• the hydrophobically modified polymers comprise, consist essentially of, or consist of a low molecular weight, non-crosslinked, linear acrylic copolymer derived from at least one first monomeric component selected from the group consisting of (meth)acrylic acid and at least one second monomeric component selected from the group consisting of one or more C 1 to C 9 alkyl (meth)acrylates, wherein the low molecular weight copolymer has a number average molecular weight of about 100,000 or less.
• Exemplary first monomeric components include (meth)acrylic acid, itaconic acid, citraconic acid, maleic acid, fumaric acid, crotonic acid, aconitic acid, and mixtures thereof.
• Exemplary second monomeric components include ethyl (meth)acrylate, butyl (meth)acrylate, 2-ethylhexyl (meth)acrylate, vinyl formate, vinyl acetate, 1-methylvinyl acetate, vinyl propionate, vinyl butyrate, vinyl 2-ethylhexanoate, vinyl pivalate, vinyl neodecanoate, and mixtures thereof.
• (meth)acrylic acid and “(meth)acrylate” are meant to include the corresponding methyl derivatives of acrylic acid and the corresponding alkyl acrylate.
• (meth)acrylic” acid refers to acrylic acid and/or methacrylic acid
• (meth)acrylate” refers to alkyl acrylate and/or alkyl methacrylate.
• said first monomeric component is selected from the group consisting of (meth)acrylic acid and said second monomeric component is selected from the group consisting of at least one C 1 to C 9 alkyl (meth)acrylate.
• the non-crosslinked, linear acrylic copolymer compounds can be synthesized via free radical polymerization techniques known in the art.
• the weight ratio of the first monomeric component to the second monomeric component utilized ranges from about 20:80 to about 50:50. In another aspect the weight ratio of the first monomeric component to the second monomeric component is about 35:65, and in a further aspect the weight ratio of first monomeric component to second monomeric component is about 25:75.
• the linear copolymeric materials useful in the methods and compositions of this invention preferably have a viscosity of 500 mPa ⁇ s or less (Brookfield RVT, 20 rpm, spindle no. 1) at a 5 wt. % polymer solids concentration in deionized water and neutralized to pH 7 with an 18 wt. % NaOH solution.
• the viscosity can range from about 1 to about 500 mPa ⁇ s in another aspect, from about 10 to about 250 mPa ⁇ s in a further aspect, and from about 15 to about 150 mPa ⁇ s in a still further aspect.
• the low molecular weight HMP is a non-crosslinked, linear acrylic copolymer having a number average molecular weight of about 15,000 to about 40,000 and is derived from methacrylic acid and ethyl acrylate.
• the low molecular weight HMP is potassium acrylates copolymer.
• the cleansing composition may optionally comprise additional ingredients typically used in cleansing compositions.
• additional ingredients typically used in cleansing compositions.
• additional ingredients conventionally used in compositions for use on skin and hair, at their art-established levels can be included.
• the cleansing composition may comprise other polymeric surfactants or monomeric surfactants.
• Anionic, nonionic, amphoteric, cationic surfactants or mixtures of the foregoing may be used as known in the art.
• Other optional ingredients include pearlescent or opacifying agents, thickeners, emollients, secondary conditioners, humectants, chelating agents, exfoliants, and additives that enhance the appearance, feel, or fragrance of the cleansing composition, such as colorants, fragrances, preservatives, pH adjusting agents, and the like.
• the cleansing composition comprises about 0.1 to about 10, preferably from about 0.25 to about 5, percent by weight SAC. In another embodiment, the cleansing composition comprises about 0.5 to about 2.5 percent by weight SAC. In further embodiment, the cleansing composition comprises about 1 to about 2.5 percent by weight SAC.
• the cleansing composition comprises about 0.1 to about 5, preferably from about 0.1 to about 2.5, percent by weight HMP. In another embodiment, the cleansing composition comprises about 0.5 to about 2.5 percent by weight HMP. In further embodiment, the cleansing composition comprises about 1 to about 2.5 percent by weight HMP.
• the cleansing composition is NEUTROGENA® Ultra Gentle Daily Cleanser, commercially available from Johnson & Johnson Consumer Inc.
• the leave-on composition comprises at least one retinoid.
• retinoid means a compound structurally similar to Vitamin A, such as those characterized by this structure:
• R represents a functional group such as CH 2 OH (retinol), CHO (retinal), CO 2 H (retinoic acid), CH 2 OCOCH 3 (retinyl acetate).
• Retinoids include other esters such as retinyl palmitate, amine derivatives, and the like.
• the retinoid is selected from retinol, retinal, retinoic acid, retinyl acetate, and retinyl palmitate.
• the retinoid is retinol.
• the leave-on composition may also optionally contain additional ingredients typically used in leave-on compositions.
• additional oil-soluble materials and/or water-soluble materials conventionally used in compositions for use on skin and hair, at their art-established levels can be included.
• surfactants or emulsifers, pearlescent or opacifying agents, thickeners, emollients, conditioners, humectants, chelating agents, exfoliants, and additives that enhance the appearance, feel, or fragrance of the cleansing composition, such as colorants, fragrances, preservatives, pH adjusting agents, and the like, can be included.
• the leave-on composition comprises at least one polar emollient having a net relative polarity index to the retinoid from about 0.5 to 2, and at least one non-polar emollient having a net relative polarity index to the retinoid from about 7 to about 10, wherein the weight ratio of said polar emollient to said non-polar emollient is from about 95 to 5 to about 40 to 60.
• the non-polar emollient may be selected from the group consisting of aromatic or linear esters, guerbet ester, mineral oil, squalane, isohexadecane, squalene, liquid paraffin, and mixtures thereof, in particular isohexadecane.
• the polar emollient may be selected from the group consisting of, propylene glycol stearyl ether, propylene glycol isostearate, and mixtures thereof, in particular propylene glycol stearyl ether.
• the leave-on composition comprises an oil-in-water emulsion comprising: (i) about 0.05 to about 0.5% by weight retinol; (ii) propylene glycol stearyl ether; and (iii) isohexadecane, wherein the weight ratio of propylene glycol stearyl ether to isohexadecane is from about 75:25 to about 50:50, and the composition does not contain any additional active agents other than retinol.
• the leave-on composition comprises about 0.001 to about 5 percent by weight retinoid. In one embodiment, the leave-on composition comprises about 0.04 to about 2 percent by weight retinoid. In one embodiment, the leave-on composition comprises about 0.04 to about 0.15 percent by weight retinoid.
• the leave-on composition is NEUTROGENA® Rapid Wrinkle Repair®, commercially available from Johnson & Johnson Consumer Inc.
• Optional Ingredients, Additional Compositions, and Product Forms are optionally available from Johnson & Johnson Consumer Inc.
• Either or both the cleansing composition and the leave-on composition may comprise other cosmetically acceptable excipients and/or active agents.
• the present methods, regimens and kits may be optionally practiced using the cleansing composition and leave-on composition with one or more additional compositions, for example moisturizers, sunscreens, and the like.
• Other cosmetically acceptable active agents for use in the cleansing composition, leave-on composition, or additional composition include for example anti-acne agents, shine control agents, anti-microbial agents, anti-inflammatory agents, anti-mycotic agents, anti-parasite agents, external analgesics, sunscreens, photoprotectors, antioxidants, keratolytic agents, surfactants, moisturizers, nutrients, vitamins, energy enhancers, anti-perspiration agents, astringents, deodorants, firming agents, anti-callous agents, agents for hair and/or skin conditioning, and other glycosaminoglycans such as hyaluronic acid.
• the amount of cosmetically active agent may range from about 0.001% to about 20% by weight of the composition, e.g., about 0.005% to about 10% by weight of the composition, such as about 0.01% to about 5% by weight of the composition.
• the cosmetically acceptable active agent may be selected for instance from hydroxy acids, benzoyl peroxide, D-panthenol carotenoids, ceramides, polyunsaturated fatty acids, essential fatty acids, enzymes, such as laccase, enzyme inhibitors, minerals, hormones, such as estrogens, steroids, such as hydrocortisone, 2-dimethylaminoethanol, copper salts, such as copper chloride, peptides, like argireline, syn-ake, and those containing copper, coenzyme Q10, amino acids, such as proline, vitamins, lactobionic acid, acetyl-coenzyme A, niacin, riboflavin, thiamin, ribose, electron transporters, such as NADH and FADH2, natural extracts, such as those from aloe vera, feverfew, oatmeal, dill, blackberry, princess tree, picia anomala, and chicory, resorcinols, such as 4-hexy
• vitamins include, but are not limited to, vitamin A, vitamin B's, such as vitamin B3, vitamin B5, and vitamin B12, vitamin C, vitamin K, and different forms of vitamin E, like alpha, beta, gamma, or delta tocopherols, or their mixtures, and derivatives thereof.
• hydroxy acids include, but are not limited, to glycolic acid, lactic acid, malic acid, salicylic acid, citric acid, and tartaric acid.
• antioxidants include, but are not limited to, water-soluble antioxidants, such as sulfhydryl compounds and their derivatives (e.g., sodium metabisulfite and N-acetyl-cysteine), lipoic acid, and dihydrolipoic acid, resveratrol, lactoferrin, and ascorbic acid, and ascorbic acid derivatives (e.g., ascorbyl palmitate and ascorbyl polypeptide).
• water-soluble antioxidants such as sulfhydryl compounds and their derivatives (e.g., sodium metabisulfite and N-acetyl-cysteine), lipoic acid, and dihydrolipoic acid, resveratrol, lactoferrin, and ascorbic acid, and ascorbic acid derivatives (e.g., ascorbyl palmitate and ascorbyl polypeptide).
• Oil-soluble antioxidants suitable for use in the compositions of this invention include, but are not limited to, butylated hydroxytoluene, retinoids (e.g., retinol and retinyl palmitate), tocopherols (e.g., tocopherol acetate), tocotrienols, and ubiquinone.
• Natural extracts containing antioxidants suitable for use in the compositions of this invention include, but not limited to, extracts containing flavonoids and isoflavonoids, and their derivatives (e.g., genistein and diadzein), extracts containing resveratrol, and the like. Examples of such natural extracts include grape seed, green tea, pine bark, and propolis.
• compositions may further include cosmetically acceptable topical carriers.
• the carrier may be from about 50% to about 99.99%, by weight, of the composition (e.g., from about 80% to about 99%, by weight, of the composition).
• the cosmetically acceptable topical carrier includes water.
• compositions may be made into a wide variety of product types that include but are not limited to lotions, creams, gels, sticks, sprays, ointments, cleansing liquid washes and solid bars, shampoos and hair conditioners, hair fixers, pastes, foams, powders, mousses, shaving creams, wipes, patches, hydrogels, film-forming products, facial masks and skin masks, films and make-up, such as foundations and mascaras.
• product types may contain a variety of cosmetically acceptable topical carriers including, but not limited to solutions, suspensions, emulsions, including microemulsions and nanoemulsions, gels, solids, and liposomes. The following are non-limiting examples of such carriers. Other carriers can be formulated by those of ordinary skill in the art.
• compositions can be formulated as solutions.
• Solutions typically include an aqueous or organic solvent (e.g., from about 50% to about 99.99% or from about 90% to about 99% of a cosmetically acceptable aqueous or organic solvent).
• suitable organic solvents include propylene glycol, polyethylene glycol, polypropylene glycol, glycerol, 1,2,4-butanetriol, sorbitol esters, 1,2,6-hexanetriol, ethanol, and mixtures thereof.
• compositions may be formulated as a solution comprising an emollient.
• Such compositions preferably contain from about 2% to about 50% of an emollient(s).
• emollients refer to materials used for the prevention or relief of dryness, such as by preventing the transepidermal loss of water from the skin.
• emollients include, but are not limited to, those set forth in the International Cosmetic Ingredient Dictionary and Handbook , eds. Pepe, Wenninger and McEwen, pp. 2930-36 (The Cosmetic, Toiletry, and Fragrance Assoc., Washington, D.C., 9th Edition, 2002) (hereinafter “ICI Handbook”).
• ICI Handbook Cosmetic, Toiletry, and Fragrance Assoc., Washington, D.C., 9th Edition, 2002
• particularly suitable emollients include vegetable oils, mineral oils, fatty esters, and the like.
• a lotion can be made from such a solution.
• Lotions typically contain from about 1% to about 20% (e.g., from about 5% to about 10%) of an emollient(s) and from about 50% to about 90% (e.g., from about 60% to about 80%) of water.
• a cream typically contains from about 5% to about 50% (e.g., from about 10% to about 20%) of an emollient(s) and from about 45% to about 85% (e.g., from about 50% to about 75%) of water.
• the composition may alternatively be anhydrous or be an ointment that includes no water but organic and/or silicone solvents, oils, lipids and waxes.
• An ointment may contain a simple base of animal or vegetable oils or semi-solid hydrocarbons.
• An ointment may contain from about 2% to about 10% of an emollient(s) plus from about 0.1% to about 2% of a thickening agent(s). Examples of thickening agents include, but are not limited to, those set forth in the ICI Handbook pp. 2979-84.
• compositions may be formulated as an emulsion. If the topical carrier is an emulsion, from about 1% to about 10% (e.g., from about 2% to about 5%) of the topical carrier contains an emulsifier(s).
• Emulsifiers may be nonionic, anionic or cationic. Examples of emulsifiers include, but are not limited to, those set forth in the ICI Handbook, pp. 2962-71.
• Lotions and creams can be formulated as emulsions.
• lotions contain from 0.5% to about 5% of an emulsifier(s).
• Such creams typically contain from about 1% to about 20% (e.g., from about 5% to about 10%) of an emollient(s); from about 20% to about 80% (e.g., from 30% to about 70%) of water; and from about 1% to about 10% (e.g., from about 2% to about 5%) of an emulsifier(s).
• Single emulsion skin care preparations such as lotions and creams, of the oil-in-water type and water-in-oil type are well-known in the cosmetic art and are useful in the subject invention.
• Multiphase emulsion compositions such as the water-in-oil-in-water type or the oil-in-water-in-oil type, are also useful in the subject invention.
• such single or multiphase emulsions contain water, emollients, and emulsifiers as essential ingredients.
• compositions can also be formulated as gels (e.g., an aqueous, alcohol, alcohol/water, or oil gel using a suitable gelling agent(s)).
• suitable gelling agents for aqueous and/or alcoholic gels include, but are not limited to, natural gums, acrylic acid and acrylate polymers and copolymers, and cellulose derivatives (e.g., hydroxymethyl cellulose and hydroxypropyl cellulose).
• Suitable gelling agents for oils include, but are not limited to, hydrogenated butylene/ethylene/styrene copolymer and hydrogenated ethylene/propylene/styrene copolymer.
• Such gels typically contain between about 0.1% and 5%, by weight, of such gelling agents.
• compositions can also be formulated into solid formulations (e.g., wax-based sticks, bars, or powders). They may be loaded onto substrates, such as woven or non-woven materials, wipes, patches, masks, articles of clothing and the like.
• pretreatment of skin with the cleansing composition comprising a LIPCA provides an increase in the activity of a retinoid thereafter topically applied.
• the retinoid is retinol
• such pretreatment provides at least about a 150%, preferably at least about 180%, increase in retinol bioactivity as measured by a change in cellular retinoic acid binding protein II (CRABPII) gene expression versus treatment with retinol alone.
• the change in cellular retinoic acid binding protein II (CRABPII) gene expression is measured using the CRABPII EXPRESSION TEST set forth in Example 1.
• CRABPII Cellular Retinoic Acid Binding Protein II
• One centimeter-diameter ex vivo skin explants were prepared from skin abdominal biopsies.
• the skin explants were maintained in KGM gold® culture medium supplemented with amphotericin B, 0.125 ⁇ g/ml at 37° C., in a water saturated atmosphere for the 48 hour duration of the test.
• the explants were placed in a conventional test plate, epidermal surface oriented up, and in sufficient culture medium to nearly but not completely immerse the sample (i.e., the epidermal surface protrudes from the upper surface of the medium).
• the mild cleanser being tested was applied to the epidermal surface protruding from the culture medium for 4 hours, followed by washing with phosphate buffered saline (PBS) and application of the RWR.
• PBS phosphate buffered saline
• the explants are removed, from which epidermal mRNA was extracted and expression of CRABPII gene was measured by Quantitative real time PCR (QRT-PCR) using a suitable sequence of oligonucleotides.
• QRT-PCR Quantitative real time PCR
• IL-la levels The in-vitro mildness (IL-la levels) of different treatments was tested as follows.
• Epidermal equivalents (EPI 200 HCF), multilayer and differentiated epidermis consisting of normal human epidermal keratinocytes, were obtained from MatTek (Ashland, Mass.). On receipt, the epidermal equivalents were incubated for 24 hours at 37° C. in maintenance medium without hydrocortisone. Equivalents were topically treated with the indicated products in Table 3 (64 volume) for 1 hour, then washed twice with PBS (phosphate buffered saline). Equivalents were then incubated for 24 hours at 37′C with maintenance medium then supernatants were analyzed for IL-la cytokine release using commercially available kits (Millipore Corp., Billerica, Mass.).

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Dermatology (AREA)
• Epidemiology (AREA)
• Birds (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical & Material Sciences (AREA)
• Gerontology & Geriatric Medicine (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• Organic Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Molecular Biology (AREA)
• Cosmetics (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicinal Preparation (AREA)

Priority Applications (13)

Applications Claiming Priority (1)

Related Child Applications (1)

Publications (1)

Family

ID=61868454

Family Applications (2)

Family Applications After (1)

Country Status (9)

Cited By (1)

Family Cites Families (17)

• 2017
  • 2017-03-31 US US15/475,516 patent/US20180280275A1/en not_active Abandoned
• 2018
  • 2018-03-27 AU AU2018202184A patent/AU2018202184A1/en not_active Abandoned
  • 2018-03-27 CA CA2999497A patent/CA2999497A1/en active Pending
  • 2018-03-27 KR KR1020180035100A patent/KR20180111585A/ko not_active Application Discontinuation
  • 2018-03-28 CN CN201810265642.2A patent/CN108685753B/zh active Active
  • 2018-03-28 MX MX2018003954A patent/MX2018003954A/es unknown
  • 2018-03-29 BR BR102018006534-3A patent/BR102018006534B1/pt active IP Right Grant
  • 2018-03-30 JP JP2018067295A patent/JP2018172373A/ja active Pending
  • 2018-04-03 EP EP20203850.1A patent/EP3789009A1/en not_active Withdrawn
  • 2018-04-03 EP EP18165449.2A patent/EP3381440A3/en not_active Withdrawn
  • 2018-11-28 US US16/202,198 patent/US20190091125A1/en not_active Abandoned
• 2023
  • 2023-04-10 JP JP2023063300A patent/JP2023076747A/ja active Pending

Also Published As

Similar Documents

Legal Events